Sanofi Releases Q1 2026 Briefing Document Ahead of April 23 Results
Sanofi announces the release of its 'Q1 2026 Briefing Document' aimed at assisting investors with financial modeling. This quarterly document addresses non-comparable items, the impact of foreign currencies, and the number of shares.
The 'Q1 2026 Briefing Document' has been made available on the 'Investors' page of Sanofi's website. Prepared each quarter, it is designed to assist in the financial modeling of quarterly results. It addresses non-comparable items, the impact of foreign currencies, and the number of shares. Sanofi's Q1 2026 results will be released on April 23, 2026.
Sanofi's Commitment to Innovation and Long-term Growth
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Sanofi is a biopharmaceutical company that innovates in R&D and leverages AI on a large scale to enhance people's lives and achieve long-term growth. The company utilizes its deep understanding of the immune system to develop drugs and vaccines that treat and protect millions of people worldwide, with an innovative pipeline. The team is driven by the goal of advancing the miracles of science to improve people’s lives by addressing the most pressing health, environmental, and societal challenges.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 22 106 millions d'euros
Quarterly revenue: 22 106 millions d'euros
Revenue growth: 11,1 %
Net income: 1 957 millions d'euros
Free cash flow: 3 724 millions d'euros
15 513 millions d'euros
Outlook / guidance
Expected revenue: 47 989 millions d'euros
Management commentary: Sanofi anticipe un taux de croissance autour de 10% à TCC, et prévoit pour le BNPA des activités à TCC une croissance légèrement supérieure à celle des ventes.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
